Gainplan LLC Buys New Shares in Nektar Therapeutics $NKTR

Key Points

• Gainplan LLC has acquired a new stake in Nektar Therapeutics, purchasing 15,000 shares valued at approximately $388,000.
• Several institutional investors significantly increased their positions in Nektar, with Almitas Capital growing its stake by over 401%.
• Nektar Therapeutics reported a quarterly earnings per share (EPS) of (2.95), surpassing analysts' expectations, and currently has a market cap of $1.10 billion.

Gainplan LLC purchased a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 15,000 shares of the biopharmaceutical company's stock, valued at approximately $388,000. Gainplan LLC owned 0.12% of Nektar Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Almitas Capital LLC grew its stake in shares of Nektar Therapeutics by 401.1% during the 1st quarter. Almitas Capital LLC now owns 4,610,872 shares of the biopharmaceutical company's stock valued at $3,135,000 after acquiring an additional 3,690,647 shares during the period. AQR Capital Management LLC lifted its holdings in Nektar Therapeutics by 336.9% during the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company's stock valued at $2,463,000 after purchasing an additional 2,807,595 shares in the last quarter. Mackenzie Financial Corp boosted its position in shares of Nektar Therapeutics by 253.1% in the first quarter. Mackenzie Financial Corp now owns 1,658,745 shares of the biopharmaceutical company's stock worth $1,128,000 after purchasing an additional 1,188,976 shares during the period. Deuterium Capital Management LLC bought a new position in shares of Nektar Therapeutics in the first quarter worth approximately $381,000. Finally, Ieq Capital LLC increased its stake in shares of Nektar Therapeutics by 2,435.4% in the first quarter. Ieq Capital LLC now owns 557,222 shares of the biopharmaceutical company's stock worth $379,000 after purchasing an additional 535,244 shares in the last quarter. Institutional investors own 75.88% of the company's stock.

Insider Transactions at Nektar Therapeutics

In other news, CEO Howard W. Robin sold 6,666 shares of the business's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $46.69, for a total value of $311,235.54. Following the sale, the chief executive officer directly owned 49,342 shares in the company, valued at $2,303,777.98. The trade was a 11.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jonathan Zalevsky sold 1,721 shares of the business's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $33.52, for a total transaction of $57,687.92. Following the completion of the sale, the insider owned 17,462 shares in the company, valued at approximately $585,326.24. This trade represents a 8.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,178 shares of company stock worth $938,776. Insiders own 3.71% of the company's stock.

Nektar Therapeutics Stock Performance

NKTR stock opened at $58.00 on Wednesday. The firm has a fifty day moving average price of $39.14 and a 200 day moving average price of $22.78. Nektar Therapeutics has a fifty-two week low of $6.45 and a fifty-two week high of $62.95. The firm has a market cap of $1.10 billion, a PE ratio of -6.59 and a beta of 1.18.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($2.95) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.13) by $0.18. The company had revenue of $11.18 million for the quarter, compared to the consensus estimate of $9.42 million. Nektar Therapeutics had a negative net margin of 163.17% and a negative return on equity of 631.43%. On average, equities analysts predict that Nektar Therapeutics will post -0.72 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Nektar Therapeutics in a research note on Saturday, September 27th. B. Riley upped their price objective on Nektar Therapeutics from $85.00 to $105.00 and gave the stock a "buy" rating in a research note on Tuesday, September 23rd. BTIG Research reissued a "buy" rating and set a $100.00 target price on shares of Nektar Therapeutics in a research note on Friday, September 19th. Finally, HC Wainwright boosted their price target on Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a report on Tuesday, June 24th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Nektar Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $91.67.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.